Pharmaceutical

The Global Biopharma Community is Now Actively Partnering for BIO-Europe(R) 2024

MUNICH, GERMANY / ACCESSWIRE / October 8, 2024 / The 30th annual BIO-Europe, the premier partnering conference for the global…

1 year ago

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow

Dr. Diwan to Discuss "Shape-Shifting", "Trojan Horse", Pathogen-Directed Attack Capability of NanoViricides Platform Technology to Combat AMR SHELTON, CT /…

1 year ago

Parexel’s Teri Karcher Named to 2024 PharmaVoice 100

Chief Drug Development Officer and Executive Vice President, Head of Launch Excellence recognized for pioneering leadership in drug development DURHAM,…

1 year ago

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

SARASOTA, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments…

1 year ago

Tonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum Antivirals

AI (Artificial Intelligence) and ML (Machine Learning) drug discovery collaboration will accelerate the development of small molecules as orally available…

1 year ago

Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome

REDWOOD CITY, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing…

1 year ago

Cerevance Achieves Second Milestone in Research Collaboration with Merck

BOSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment…

1 year ago

Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts

CORAL GABLES, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "the Company") (Nasdaq: CPRX), a commercial-stage…

1 year ago

ImmuneSensor Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead cGAS Inhibitor Drug Candidate, IMSB301

Safety, pharmacokinetics and target engagement data from first-in-human Phase 1 clinical trial in healthy volunteers will potentially enable rapid advancement…

1 year ago